A path to efficient gene editing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Effects of Medium-Chain Versus Medium- and Long-Chain Triglycerides, Combined with Carotenoids, in a High-Fat Diet on Obese Mice.Foods (Basel, Switzerland) · 2026
   Article
2. Pyroptosis-Inducing Biomaterials Pave the Way for Transformative Antitumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
   Review
3. Precise homology-directed installation of large genomic edits in human cells with cleaving and nicking high-specificity Cas9 variants.Nucleic acids research · 2023
   Article
4. Two-dimensional nanostructures based '-onics' and '-omics' in personalized medicine.Nanophotonics (Berlin, Germany) · 2022
   Review
5. A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use.Oncoscience · 2022
   Article
6. Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet.PloS one · 2020
   Article
7. Omics Meeting Onics: Towards the Next Generation of Spectroscopic-Based Technologies in Personalized Medicine.Journal of personalized medicine · 2019
   Article
8. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.Journal of hematology & oncology · 2019
   Review

Corrections and comments

• Comment on
  p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.2018
• Comment on
  CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as